You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ROS1

Showing 26 - 50 of 991
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB

Recruiting
  • Non Small Cell Lung Cancer
  • anti-PD-1 or anti-PD-L1
  • +2 more
  • Shanghai, China
    Oncology Department, Shanghai Chest Hospital
Jul 26, 2022

Advanced Solid Malignant Tumors Trial in Fukuoka, Osaka, Tokyo (DS-6051b)

Active, not recruiting
  • Advanced Solid Malignant Tumors
  • Fukuoka, Japan
  • +2 more
Jan 18, 2022

ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

Active, not recruiting
  • ALK or ROS1-positive NSCLC
  • Fuzhou, Fujian, China
  • +9 more
Aug 30, 2022

Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)

Recruiting
  • Soft Tissue Sarcoma
  • +2 more
  • Blood and tumor samples
  • Clermont-Ferrand, France
  • +9 more
Dec 8, 2021

Lung Cancer, Nonsmall Cell Trial in Aurora (Crizotinib)

Completed
Has Results
  • Lung Cancer, Nonsmall Cell
  • Aurora, Colorado
    University of Colorado Denver
Jan 19, 2022

NSCLC (NSCLC) Trial in Jinan (WX-0593 Tablets, chemo, Thoracic Radiation Therapy(TRT))

Recruiting
  • Non-small Cell Lung Cancer (NSCLC)
  • WX-0593 Tablets
  • +2 more
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Apr 24, 2022

Non Small Cell Lung Cancer Metastatic Trial in France (Lorlatinib)

Recruiting
  • Non Small Cell Lung Cancer Metastatic
  • Aix-en-Provence, France
  • +38 more
Aug 9, 2022

NSCLC Trial in Worldwide (Repotrectinib, Crizotinib)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Augusta, Georgia
  • +40 more
Nov 29, 2023

Solid Tumor, Haematological Malignancy, Malignancy Trial in United Kingdom (Entrectinib)

Recruiting
  • Solid Tumor
  • +10 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Non-Small-Cell Lung Cancer, NSCLC Trial in Nagoya, Barcelona, Taipei (Lorlatinib)

Recruiting
  • Non-Small-Cell Lung Cancer
  • NSCLC
  • Nagoya, Aichi, Japan
  • +2 more
Jul 21, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))

Recruiting
  • Locally Advanced Solid Tumors
  • +3 more
  • Oral repotrectinib (TPX-0005)
  • Los Angeles, California
  • +27 more
Aug 9, 2022

Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Tumor, Advanced ALK+ or ROS1+Solid Tumors Trial in Worldwide (Midazolam,

Completed
  • Carcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid Tumors
  • Paris, Ile-de-france, France
  • +13 more
May 19, 2021

Lorlatinib in ALK/ROS1 Metastatic NSCLC Compassionate Use

Recruiting
  • Metastatic Non Small Cell Lung Cancer
  • Santiago De Compostela, A Coruña, Spain
  • +24 more
Jun 1, 2022

Mediastinal Lymphadenopathy, Hilar Lymphadenopathy, Lymphoma Trial in Ancona (No suction EBUS-TBNA, Passive suction through

Not yet recruiting
  • Mediastinal Lymphadenopathy
  • +9 more
  • No suction EBUS-TBNA
  • +2 more
  • Ancona, Italy
    Pulmonary Diseases Unit, Department of Immunoallergic and Respir
May 25, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Korea, Republic of, United States (Entrectinib)

Completed
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Orange, California
  • +9 more
Jun 7, 2021

NSCLC (NSCLC) Trial in Boston (Lorlatinib)

Recruiting
  • Non-Small Cell Lung Cancer (NSCLC)
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 7, 2021

Activating ALK Gene Mutation Negative, Activating EGFR Gene Mutation Negative, Activating ROS1 Gene Mutation Negative Trial in

Completed
  • Activating ALK Gene Mutation Negative
  • +7 more
  • Counseling
  • +2 more
  • Philadelphia, Pennsylvania
    Sidney Kimmel Cancer Center at Thomas Jefferson University
Sep 7, 2022

NSCLC Metastatic, Targetable Oncogenes (EGFR, ALK, ROS1) Trial in Boston (SBRT with protons or photons)

Active, not recruiting
  • Non-small Cell Lung Cancer Metastatic
  • Targetable Oncogenes (EGFR, ALK, ROS1)
  • SBRT with protons or photons
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 22, 2021

Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Trial in Shanghai (SIM1803-1A)

Recruiting
  • Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
  • Shanghai, China
    Shanghai Chest Hospital
Jan 11, 2021

NSCLC Trial in Shanghai (Alkotinib)

Recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Eastern Hospital
Jun 21, 2021

Non Small Cell Lung Cancer Trial in Shanghai (AB-106)

Recruiting
  • Non Small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Jun 17, 2021

ALCMI-006: A Prospective Biospecimen Collection Study From

Completed
  • ROS1-fusion Positive Tumor
  • Biospecimens collection
  • San Carlos, California
    ALCMI
Sep 6, 2020

NSCLC Stage IIIB, NSCLC Stage IV, EGFR Gene Mutation Trial in France (Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab,

Recruiting
  • NSCLC Stage IIIB
  • +4 more
  • Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab
  • Carboplatin + Pemetrexed + Atezolizumab
  • Angers, France
  • +30 more
Jun 7, 2021

NSCLC, Crizotinib, ALK Gene Rearrangement or ROS1 Gene Rearrangement Trial in France

Completed
  • NSCLC
  • +2 more
    • Aix en Provence, France
    • +25 more
    Sep 24, 2021

    Non Small Cell Lung Cancer Trial in Worldwide (Taletrectinib)

    Recruiting
    • Non Small Cell Lung Cancer
    • Beverly Hills, California
    • +58 more
    Dec 13, 2022